Lucira Health, Inc.

Lucira Health, Inc. (LHDX) priced its initial public offering on Feb 8, 2021 at $17.00 per share, within its $15.00–$17.00 range, raising $153M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $628.4M. BofA Securities was lead-left underwriter, joined by William Blair. Cooley advised the company and A&O Shearman advised the underwriters.

Lucira Health, Inc. is a medical technology company developing and selling infectious disease test kits. Its single-use, battery-powered, palm-sized kits deliver molecular test results with laboratory-level accuracy on the spot, aimed at mass-population testing needs highlighted by the COVID-19 pandemic.

Status

IPO

Ticker

LHDX

Exchange

Nasdaq Global Select

Priced

Feb 8, 2021

IPO price

$17.00

Price range

$15.00–$17.00

Raised

$153M

Market cap at IPO price

$628.4M

First filed

Jan 15, 2021

Underwriters

BofA Securities and William Blair

Company counsel

Cooley

Underwriters' counsel

A&O Shearman

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.